Amarin (AMRN) Vascepa Exclusivity Status Not in FDA Orange Book March Update

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/19/2026

1. KLAR
2. KEYS
3. PANW
4. HD
5. DVLT

6. MRNA
7. PGR
8. EPM
9. MRCY
10. LOW

April 12, 2013 10:35 AM EDT

Price: $14.29 +1.13%

Overall Analyst Rating:
SELL (= Flat)

Amarin Corp Plc (Nasdaq: AMRN) Vascepa exclusivity status isn't in FDA Orange Book update for March.

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!